Literature DB >> 1663361

In vitro and in vivo pharmacologic activities of antisense oligonucleotides.

C K Mirabelli1, C F Bennett, K Anderson, S T Crooke.   

Abstract

The use of antisense oligonucleotide as pharmacologic agents is a derivative of the central dogma of molecular biology and knowledge of the physical and chemical properties that govern the structure of nucleic acids. Oligonucleotides have been reported to inhibit the growth of a large number of viruses in cell culture, as well as the expression of numerous oncogenes, a variety of normal genes and transfected reporter genes controlled by several regulatory elements. The therapeutic activity of antisense compounds in animal disease models have also been reported. This review provides some general conclusions and trends regarding the pharmacologic action of antisense oligonucleotides, that can be formulated from studies previously reported in the literature. In addition, data is highlighted for two specific examples in which antisense oligonucleotides have demonstrated activity against herpes viruses and intracellular adhesion molecule RNA targets.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1663361

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  11 in total

1.  Proteolipid protein regulates the survival and differentiation of oligodendrocytes.

Authors:  X Yang; R P Skoff
Journal:  J Neurosci       Date:  1997-03-15       Impact factor: 6.167

Review 2.  Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.

Authors:  R A Stull; F C Szoka
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

Review 3.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 4.  Application of antisense DNA method for the study of molecular bases of brain function and behavior.

Authors:  S Ogawa; D W Pfaff
Journal:  Behav Genet       Date:  1996-05       Impact factor: 2.805

5.  Bioavailability of antisense oligonucleotides in neuroblastoma cells: comparison of efficacy among different types of molecules.

Authors:  M V Corrias; F Guarnaccia; M Ponzoni
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

6.  Deoxyribonucleic acid triplex formation inhibits granulocyte macrophage colony-stimulating factor gene expression and suppresses growth in juvenile myelomonocytic leukemic cells.

Authors:  M Kochetkova; P O Iversen; A F Lopez; M F Shannon
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

7.  DNA as therapeutics; an update.

Authors:  P Saraswat; R R Soni; A Bhandari; B P Nagori
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

8.  Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region.

Authors:  R F Azad; V B Driver; K Tanaka; R M Crooke; K P Anderson
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

9.  In vivo transcription of a progesterone-responsive gene is specifically inhibited by a triplex-forming oligonucleotide.

Authors:  N H Ing; J M Beekman; D J Kessler; M Murphy; K Jayaraman; J G Zendegui; M E Hogan; B W O'Malley; M J Tsai
Journal:  Nucleic Acids Res       Date:  1993-06-25       Impact factor: 16.971

10.  Antisense oligodeoxynucleotides: synthesis, biophysical and biological evaluation of oligodeoxynucleotides containing modified pyrimidines.

Authors:  Y S Sanghvi; G D Hoke; S M Freier; M C Zounes; C Gonzalez; L Cummins; H Sasmor; P D Cook
Journal:  Nucleic Acids Res       Date:  1993-07-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.